Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Epigenetics Drugs and Diagnostic Technologies Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Epigenetics Drugs and Diagnostic Technologies Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 HDAC inhibitors
      • 1.3.3 DNMT inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global Epigenetics Drugs and Diagnostic Technologies Market Share by Application (2019-2025)
      • 1.4.2 Non coding RNA’s
      • 1.4.3 Micro RNA’s
      • 1.4.4 Histone modifications
      • 1.4.5 DNA methylation
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Epigenetics Drugs and Diagnostic Technologies Market Size
      • 2.1.1 Global Epigenetics Drugs and Diagnostic Technologies Revenue 2014-2025
      • 2.1.2 Global Epigenetics Drugs and Diagnostic Technologies Sales 2014-2025
    • 2.2 Epigenetics Drugs and Diagnostic Technologies Growth Rate by Regions
      • 2.2.1 Global Epigenetics Drugs and Diagnostic Technologies Sales by Regions 2014-2019
      • 2.2.2 Global Epigenetics Drugs and Diagnostic Technologies Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Epigenetics Drugs and Diagnostic Technologies Sales by Manufacturers
      • 3.1.1 Epigenetics Drugs and Diagnostic Technologies Sales by Manufacturers 2014-2019
      • 3.1.2 Epigenetics Drugs and Diagnostic Technologies Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Epigenetics Drugs and Diagnostic Technologies Revenue by Manufacturers (2014-2019)
      • 3.2.2 Epigenetics Drugs and Diagnostic Technologies Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Epigenetics Drugs and Diagnostic Technologies Market Concentration Ratio (CR5 and HHI)
    • 3.3 Epigenetics Drugs and Diagnostic Technologies Price by Manufacturers
    • 3.4 Key Manufacturers Epigenetics Drugs and Diagnostic Technologies Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Epigenetics Drugs and Diagnostic Technologies Market
    • 3.6 Key Manufacturers Epigenetics Drugs and Diagnostic Technologies Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 HDAC inhibitors Sales and Revenue (2014-2019)
      • 4.1.2 DNMT inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global Epigenetics Drugs and Diagnostic Technologies Sales Market Share by Type
    • 4.3 Global Epigenetics Drugs and Diagnostic Technologies Revenue Market Share by Type
    • 4.4 Epigenetics Drugs and Diagnostic Technologies Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Epigenetics Drugs and Diagnostic Technologies Sales by Application

    6 United States

    • 6.1 United States Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Company
    • 6.2 United States Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Type
    • 6.3 United States Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Application

    7 European Union

    • 7.1 European Union Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Company
    • 7.2 European Union Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Type
    • 7.3 European Union Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Application

    8 China

    • 8.1 China Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Company
    • 8.2 China Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Type
    • 8.3 China Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Company
    • 9.2 Rest of World Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Type
    • 9.3 Rest of World Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Application
    • 9.4 Rest of World Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Countries
      • 9.4.1 Rest of World Epigenetics Drugs and Diagnostic Technologies Sales by Countries
      • 9.4.2 Rest of World Epigenetics Drugs and Diagnostic Technologies Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Varlix Plc
      • 10.1.1 Varlix Plc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.1.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.1.5 Varlix Plc Recent Development
    • 10.2 Topotarget
      • 10.2.1 Topotarget Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.2.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.2.5 Topotarget Recent Development
    • 10.3 Syndax Pharmaceuticals
      • 10.3.1 Syndax Pharmaceuticals Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.3.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.3.5 Syndax Pharmaceuticals Recent Development
    • 10.4 Spectrum Pharmaceuticals
      • 10.4.1 Spectrum Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.4.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.4.5 Spectrum Pharmaceuticals Recent Development
    • 10.5 Promega
      • 10.5.1 Promega Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.5.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.5.5 Promega Recent Development
    • 10.6 Novartis
      • 10.6.1 Novartis Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.6.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.6.5 Novartis Recent Development
    • 10.7 Oncolys BioPharma
      • 10.7.1 Oncolys BioPharma Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.7.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.7.5 Oncolys BioPharma Recent Development
    • 10.8 MDxHealth
      • 10.8.1 MDxHealth Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.8.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.8.5 MDxHealth Recent Development
    • 10.9 Merck
      • 10.9.1 Merck Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.9.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.9.5 Merck Recent Development
    • 10.10 Illumina
      • 10.10.1 Illumina Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Epigenetics Drugs and Diagnostic Technologies
      • 10.10.4 Epigenetics Drugs and Diagnostic Technologies Product Introduction
      • 10.10.5 Illumina Recent Development
    • 10.11 Epizyme
    • 10.12 Forum Pharmaceuticals
    • 10.13 EpiGentek
    • 10.14 Chroma Therapeutics
    • 10.15 Celleron Therapeutics
    • 10.16 CellCentric
    • 10.17 Astex Pharmaceuticals
    • 10.18 Acetylon Pharmaceuticals
    • 10.19 4SC AG
    • 10.20 Eisai
    • 10.21 Pharmacyclics

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Epigenetics Drugs and Diagnostic Technologies Sales Channels
      • 11.2.2 Epigenetics Drugs and Diagnostic Technologies Distributors
    • 11.3 Epigenetics Drugs and Diagnostic Technologies Customers

    12 Market Forecast

    • 12.1 Global Epigenetics Drugs and Diagnostic Technologies Sales and Revenue Forecast 2019-2025
    • 12.2 Global Epigenetics Drugs and Diagnostic Technologies Sales Forecast by Type
    • 12.3 Global Epigenetics Drugs and Diagnostic Technologies Sales Forecast by Application
    • 12.4 Epigenetics Drugs and Diagnostic Technologies Forecast by Regions
      • 12.4.1 Global Epigenetics Drugs and Diagnostic Technologies Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Epigenetics Drugs and Diagnostic Technologies Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      The drugs and technologies that treat the reletive diseases
      Rising incidence of gene expression changes due to chemical modifications in DNA or chromatin is the major factor driving the growth of epigenetics drugs and diagnostic technologies market
      Increasing demand for epigenetics drugs and diagnostic technology is a direct consequence of rapidly increasing incidences of oncological disorders
      In 2019, the market size of Epigenetics Drugs and Diagnostic Technologies is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Epigenetics Drugs and Diagnostic Technologies.

      This report studies the global market size of Epigenetics Drugs and Diagnostic Technologies, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Epigenetics Drugs and Diagnostic Technologies sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Varlix Plc
      Topotarget
      Syndax Pharmaceuticals
      Spectrum Pharmaceuticals
      Promega
      Novartis
      Oncolys BioPharma
      MDxHealth
      Merck
      Illumina
      Epizyme
      Forum Pharmaceuticals
      EpiGentek
      Chroma Therapeutics
      Celleron Therapeutics
      CellCentric
      Astex Pharmaceuticals
      Acetylon Pharmaceuticals
      4SC AG
      Eisai
      Pharmacyclics

      Market Segment by Product Type
      HDAC inhibitors
      DNMT inhibitors

      Market Segment by Application
      Non coding RNA’s
      Micro RNA’s
      Histone modifications
      DNA methylation

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Epigenetics Drugs and Diagnostic Technologies status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Epigenetics Drugs and Diagnostic Technologies manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Epigenetics Drugs and Diagnostic Technologies are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now